Endo Faces Securities Suit Over Unit's Price-Fixing Probe

An Endo investor on Monday lodged a proposed class action in New York federal court accusing the drugmaker of failing to disclose that its subsidiary Par Pharmaceutical may have colluded with...

Already a subscriber? Click here to view full article